KALA BIO's 15min chart shows bullish crossover, bullish marubozu pattern.

According to KALA BIO's 15-minute chart, a golden cross of the KDJ indicator and a bullish marubozu pattern were observed on July 7, 2025 at 10:00. This indicates a shift in the stock price momentum towards the upside, with potential for further increase. As buyers continue to exert control over the market, it is likely that bullish momentum will persist.

Kala Pharmaceuticals Inc. (NASDAQ: KALA), a clinical-stage biopharmaceutical company focused on developing innovative eye disease therapies, has shown signs of bullish momentum in its stock price. According to the 15-minute chart, a golden cross of the KDJ indicator and a bullish marubozu pattern were observed on July 7, 2025, at 10:00. This technical indicator shift suggests a potential upward trend in the stock price, with buyers exerting control over the market.

Recent Financial Performance

In the first quarter of 2025, KALA reported financial results that indicate a reduction in net loss and decreased expenses. The company ended Q1 2025 with $42.2 million in cash, which is expected to fund operations into Q1 2026 [3]. The net loss for the quarter was $8.9 million, a decrease from $11.8 million in Q1 2024, with a reduction in general and administrative (G&A) expenses of $4.6 million and research and development (R&D) expenses of $6.1 million.

Clinical Trial Updates

KALA's lead candidate, KPI-012, based on their proprietary MSC-S platform, is currently in a Phase 2b clinical trial (CHASE) for Persistent Corneal Epithelial Defect (PCED). The company has randomized 87 patients and expects topline data in Q3 2025. KPI-012 aims to be a first-in-class treatment for PCED, targeting an estimated U.S. market of 100,000 patients [4].

Upcoming Events

KALA BIO has several upcoming events that could provide further insights into the company's progress and potential for growth:

1. Virtual Key Opinion Leader (KOL) Event: KALA BIO will host a virtual KOL event on July 16, 2025, at 4:00 p.m. ET, to discuss the potential of KPI-012 for the treatment of PCED. The event will feature presentations from distinguished ophthalmology experts and interim CEO Todd Bazemore [1].

2. Jefferies Global Healthcare Conference: KALA BIO will present at the Jefferies Global Healthcare Conference on June 5, 2025, at 1:25 p.m. ET in New York, NY. The company's management team will deliver a presentation and be available for one-on-one meetings [2].

3. TD Cowen 45th Annual Health Care Conference: KALA BIO will participate in the TD Cowen 45th Annual Health Care Conference on March 5, 2025, at 11:50 a.m. ET in Boston, MA. The company's management team will deliver a presentation and be available for one-on-one meetings [5].

Conclusion

The recent financial performance, clinical trial updates, and upcoming events suggest that Kala Pharmaceuticals is well-positioned for further growth. Investors and financial professionals should closely monitor the company's progress and the potential impact of these upcoming events on the stock price.

References:

[1] https://www.stocktitan.net/news/KALA/
[2] https://www.stocktitan.net/news/KALA/
[3] https://www.stocktitan.net/news/KALA/
[4] https://www.stocktitan.net/news/KALA/
[5] https://www.stocktitan.net/news/KALA/